Skip to Main Content

Here is STAT’s Biotech Scorecard, our regular ledger of stock-moving biotech events, for the fourth quarter.

After months spent drafting comfortably in Amgen’s KRAS-blocking wake, the time has finally come for Mirati Therapeutics to show its own work. Up until now, Amgen has done all the heavy lifting when it comes to showcasing clinical data on drugs targeting KRAS, the buzzy cancer protein once thought to be “undruggable” because of its spherical structure. Does Mirati have a better KRAS-blocking drug, or not? The first opportunity to compare the rival KRAS drugs comes on Oct. 28, when Mirati is expected to present its first clinical data at a cancer conference.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.